A MIXED BAG

When it comes to impending drug approvals, these appear to be the worst of times and the best of times. While some therapeutic areas like oncology continue to draw lots of research and development activity, other areas such as infectious disease seem to be left out of the progress of modern medicine...

Full description

Saved in:
Bibliographic Details
Published in:Drug Topics 2006-12, Vol.150 (23), p.HSE1
Main Author: Beyzarov, Elena
Format: Article
Language:English
Subjects:
Blood pressure
Breast cancer
Business forecasts
Cancer therapies
Chemotherapy
Clinical trials
Drug dosages
Glucose
Hypertension
Infectious diseases
Kinases
Metastasis
Nosocomial infections
Oncology
Pharmaceutical industry
Prostate cancer
R&D
Regulatory approval
Research & development
Staphylococcus infections
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:When it comes to impending drug approvals, these appear to be the worst of times and the best of times. While some therapeutic areas like oncology continue to draw lots of research and development activity, other areas such as infectious disease seem to be left out of the progress of modern medicine. Looking at what other drugs are in the offing for next year, market forecasters such as IMS Health are predicting 25 to 35 product launches, a number that is comparable to this year's expected 30 launches. Among the predicted blockbusters for 2007 are two oral agents from a new class of drugs being developed for type 2 diabetes. One interesting trend in the lineup for 2007 is the development of a heavy percentage of biotech drugs for immune-related conditions such as rheumatoid arthritis [RA], cancer, and systemic lupus erythematosus [SLE].
ISSN:0012-6616
1937-8157